We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
126
uniQure
QURE
$2.93B
$1.78M 0.07%
241,021
– –
HALO icon
127
Halozyme
HALO
$9.88B
$1.73M 0.07%
200,000
– –
MNTA
128
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.66M 0.07%
153,700
– –
DCOY
129
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
MACK
130
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.54M 0.06%
36,351
-36,083
-50% -$1.97M
AMGN icon
131
CALL
Amgen
AMGN
$209B
$1.54M 0.06%
+10,100
New +$1.57M
FOLD
132
DELISTED
Amicus Therapeutics
FOLD
$1.41M 0.06%
258,000
– –
CDTX
133
DELISTED
Cidara Therapeutics
CDTX
$1.37M 0.06%
6,624
+2,999
+83% +$726K
RCKT icon
134
Rocket Pharmaceuticals
RCKT
$351M
$1.34M 0.05%
45,191
-76,657
-63% -$2.7M
CMRX
135
DELISTED
Chimerix, Inc.
CMRX
$1.21M 0.05%
308,892
– –
RVNC
136
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.02M 0.04%
75,000
+30,000
+67% +$530K
ESPR
137
DELISTED
Esperion Therapeutics
ESPR
$1.02M 0.04%
102,800
– –
TTPH
138
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$827K 0.03%
9,616
– –
QHC
139
DELISTED
Quorum Health Corporation
QHC
$815K 0.03%
+76,118
New +$887K
GNMK
140
DELISTED
GenMark Diagnostics, Inc
GNMK
$812K 0.03%
93,349
– –
BLCM
141
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$778K 0.03%
6,000
– –
AFMD
142
DELISTED
Affimed
AFMD
$730K 0.03%
29,421
– –
CLDX icon
143
Celldex Therapeutics
CLDX
$3.02B
$464K 0.02%
7,053
– –
XNCR icon
144
Xencor
XNCR
$1.59B
$380K 0.02%
20,000
– –
RMR icon
145
The RMR Group
RMR
$333M
$230K 0.01%
7,441
– –
LRMR icon
146
Larimar Therapeutics
LRMR
$398M
$80K ﹤0.01%
1,109
– –
ABBV icon
147
AbbVie
ABBV
$455B
$10K ﹤0.01%
156
– –
BAX icon
148
Baxter International
BAX
$13.8B
– –
-319,600
Closed -$13.1M
BMY icon
149
Bristol-Myers Squibb
BMY
$132B
– –
-202,600
Closed -$12.9M
HR icon
150
Healthcare Realty
HR
$7.46B
– –
-178,033
Closed -$5.24M
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.